Radiopharm Theranostics Limited Sponsored ADR (RADX)
NASDAQ:RADX
Want to see RADX full AI Analyst Report?
RADX Stock Chart & Stats
$4.58
-$0.80(-17.20%)
At close: 4:00 PM EST
$4.58
-$0.80(-17.20%)
Day’s Range― - ―
52-Week Range$3.62 - $16.25
Previous CloseN/A
Volume12.21K
Average Volume (3M)287.79K
Market Cap
$49.69M
Enterprise Value$19.79M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Sep 24, 2026EPS Estimate
-2.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.11
Shares Outstanding11,814,054
10 Day Avg. Volume45,935
30 Day Avg. Volume287,787
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.09
Price to Sales (P/S)13.46
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.33Price Target Upside343.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-3.15
Revenue Forecast (FY)$1.63M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt materially lowers refinancing risk and gives Radiopharm flexibility to fund R&D and JV commitments without immediate interest burdens. Over a multi‑month horizon this conservative leverage profile preserves strategic optionality while the company advances clinical programs.
Increased Stake In MD Anderson JVRaising ownership to 87.5% strengthens Radiopharm’s control and economic exposure to the Radiopharm Ventures pipeline. This increases upside capture from Betabart and other assets, aligns strategy with MD Anderson expertise, and solidifies a long‑term foothold in radiopharmaceutical oncology.
Clinical Progression: First Patient DosedDosing the first patient moves Betabart from IND to active clinical testing, a durable de‑risking milestone. Clinical entry enables generation of human safety, dosimetry and preliminary efficacy data that can drive partnering, regulatory pathways, and long‑term commercial prospects if trials progress positively.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicates ongoing burn to support development activities. Over the medium term this constrains the company’s ability to self‑fund parallel programs, forcing reliance on financings or partnerships that can dilute shareholders or delay investments.
Sustained Unprofitability & Deep MarginsLarge operating and net losses relative to sales show no near‑term path to positive margins. Persistent unprofitability erodes equity value and limits reinvestment capacity; absent clear commercialization or major licensing revenue, margin recovery may take multiple years.
Ongoing Funding NeedsWorsening FCF and explicit ongoing funding needs create structural dependency on external capital or partner deals. That dependence risks dilution, timing mismatches for trial milestones, and potential reprioritization of programs if capital markets or partners tighten over the coming months.
Radiopharm Theranostics Limited Sponsored ADR News
RADX FAQ
What was Radiopharm Theranostics Limited Sponsored ADR’s price range in the past 12 months?
Radiopharm Theranostics Limited Sponsored ADR lowest stock price was $3.62 and its highest was $16.25 in the past 12 months.
What is Radiopharm Theranostics Limited Sponsored ADR’s market cap?
Radiopharm Theranostics Limited Sponsored ADR’s market cap is $49.69M.
When is Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date?
Radiopharm Theranostics Limited Sponsored ADR’s upcoming earnings report date is Sep 24, 2026 which is in 95 days.
How were Radiopharm Theranostics Limited Sponsored ADR’s earnings last quarter?
Radiopharm Theranostics Limited Sponsored ADR released its earnings results on Feb 27, 2026. The company reported -$2.106 earnings per share for the quarter, missing the consensus estimate of -$2.096 by -$0.01.
Is Radiopharm Theranostics Limited Sponsored ADR overvalued?
According to Wall Street analysts Radiopharm Theranostics Limited Sponsored ADR’s price is currently Undervalued.
Does Radiopharm Theranostics Limited Sponsored ADR pay dividends?
Radiopharm Theranostics Limited Sponsored ADR does not currently pay dividends.
What is Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate?
Radiopharm Theranostics Limited Sponsored ADR’s EPS estimate is -2.55.
How many shares outstanding does Radiopharm Theranostics Limited Sponsored ADR have?
Radiopharm Theranostics Limited Sponsored ADR has 11,814,054 shares outstanding.
What happened to Radiopharm Theranostics Limited Sponsored ADR’s price movement after its last earnings report?
Radiopharm Theranostics Limited Sponsored ADR reported an EPS of -$2.106 in its last earnings report, missing expectations of -$2.096. Following the earnings report the stock price went up 0.201%.
Which hedge fund is a major shareholder of Radiopharm Theranostics Limited Sponsored ADR?
Currently, no hedge funds are holding shares in RADX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Radiopharm Theranostics Limited Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$20.33 (343.96% Upside)
$20.33 (343.96% Upside)
Blogger Sentiment
Neutral
RADX Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.39%
12-Months-Change
Fundamentals
Return on Equity
-93.08%
Trailing 12-Months
Asset Growth
6.21%
Trailing 12-Months
Company Description
Radiopharm Theranostics Limited Sponsored ADR
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
RADX Stock 12 Month Forecast
Average Price Target
$20.33
▲(343.96% Upside)
Technical Analysis
Serina Therapeutics
―
Celularity
―
Barinthus Biotherapeutics
―
Acrivon Therapeutics, Inc.
―
Telomir Pharmaceuticals, Inc.
―